
Mgr. Kryštof Hlaváč
odborný pracovník - PhD student – Výzkumná skupina Marka Mráze
korespondenční adresa:
Kamenice 753/5, 625 00 Brno
e‑mail: | Krystof.Hlavac@ceitec.muni.cz |
---|
Počet publikací: 14
2025
-
FoxO1 signaling in B cell malignancies and its therapeutic targeting.
FEBS Letters, rok: 2025, DOI
2024
-
Co-culture with CD40L, IL4 and IL21 expressing stromal cells induces robust CLL cell proliferation in vitro and in PDX co-transplantations
Rok: 2024, druh: Konferenční abstrakty
-
FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia
The Journal of Clinical Investigation, rok: 2024, ročník: 134, vydání: 23, DOI
-
MOLECULAR MECHANISM OF NON-GENETIC ADAPTATION TO BTK INHIBITOR THERAPY IN CLL
Rok: 2024, druh: Konferenční abstrakty
-
STROMAL CELLS ENGINEERED TO EXPRESS T CELL FACTORS INDUCE ROBUST CLL CELL PROLIFERATION IN VITRO AND IN PDX COTRANSPLANTATIONS ALLOWING THE IDENTIFICATION OF ANTI-PROLIFERATIVE DRUGS
Rok: 2024, druh: Konferenční abstrakty
-
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug
Leukemia, rok: 2024, ročník: 38, vydání: 8, DOI
2023
-
FOX01-rictor AXIS induces AKT phosporylation during CLL cell adaptation to BCR inhibitors: Implications for combinatorial therapy.
Rok: 2023, druh: Konferenční abstrakty
-
FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy.
Rok: 2023, druh: Konferenční abstrakty
-
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia.
Rok: 2023, druh: Konferenční abstrakty
-
Molecular response of chronic lymphocytic leukemia cells to targeted therapy.
Rok: 2023, druh: Konferenční abstrakty